Tonix Pharmaceuticals/$TNXP
1D1W1MYTD1Y5YMAX
Capital at risk
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
- Ticker
- $TNXP
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 142
- Headquarters
- Berkeley Heights, United States
- Website
- www.tonixpharma.com
TNXP Metrics
BasicAdvanced
$202M
-
-$12.49
1.69
-
Price and volume
Market cap
$202M
Beta
1.69
52-week high
$29.19
52-week low
$9.40
Average daily volume
448K
Financial strength
Current ratio
6.608
Quick ratio
6.117
Long term debt to equity
0.005
Total debt to equity
0.006
Interest coverage (TTM)
-1,858.71%
Profitability
EBITDA (TTM)
-163.302
Gross margin (TTM)
83.83%
Net profit margin (TTM)
-548.64%
Operating margin (TTM)
-568.43%
Revenue per employee (TTM)
$200,000
Management effectiveness
Return on assets (TTM)
-46.84%
Return on equity (TTM)
-81.82%
Valuation
Price to revenue (TTM)
5.167
Price to book
0.91
Price to tangible book (TTM)
0.89
Price to free cash flow (TTM)
-0.951
Free cash flow yield (TTM)
-105.16%
Free cash flow per share (TTM)
-12.366
Growth
Revenue change (TTM)
196.02%
Earnings per share change (TTM)
-38.12%
What the Analysts think about TNXP
Analyst ratings (Buy, Hold, Sell) for Tonix Pharmaceuticals stock.
Analyst projections of the future price of Tonix Pharmaceuticals stock.
TNXP Financial Performance
Revenues and expenses
TNXP Earnings Performance
Company profitability
Upcoming events
No upcoming events
TNXP News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.